Mubadala

Tracked participation in 4 Atlas companies, with 0 explicitly attributed leads.

4portfolio companies

4round participations

0lead positions

Nov 2025latest activity

Capital activity

Portfolio

CompanyLatest valuationFirst → latestRoundsRoleAttributed partner

ITIambic TherapeuticsScienceIambic Therapeutics (formerly Entos) is a clinical-stage life science and technology company developing…$8.4Mvaluation$476MraisedRecent roundsOversubscribed financing round (company described as >$100M) · Nov 2025$100M · Abingworth, Alexandria Venture Investments +15Series B extension (oversubscribed) · Jun 2024$50M · led by Exor Ventures, Mubadala CapitalSeries B (oversubscribed) · Oct 2023$100M · led by Abingworth, Ascenta CapitalIambic Therapeutics—Nov 2025 → Nov 20251 roundParticipant—

CCrusoeNeocloudsCrusoe is a vertically integrated AI infrastructure provider built around energy-first compute. The company says it…$10Bvaluation$3.8BraisedRecent roundsSeries E · Oct 2025$1.4B · led by Mubadala Capital, Valor Equity PartnersDebt financing (credit facility) · Jun 2025$750M · led by Brookfield Asset ManagementDebt financing (credit facility) · Mar 2025$225M · led by Upper90 Capital ManagementCrusoe$2.8BDec 2024 → Dec 20241 roundParticipant—

RRecursionScienceRecursion is a clinical-stage TechBio company building an industrialized, AI-native drug discovery and development…$938.3MraisedRecent roundsPublic offering (underwritten) · Jun 2024$200M · Public shareholders (offering investors)Strategic investment (private investment in public equity / PIPE) · Jul 2023$50M · led by NVIDIAInitial Public Offering (IPO) / Public offering (pricing) · Apr 2021$436.4M · Baillie Gifford & Co. (clients incl. Scottish Mortgage Investment Trust plc), Mubadala Investment Company (entities affiliated) +1Recursion—Sep 2020 → Sep 20201 roundParticipant—

OOwkin—— → —1 roundParticipant—

DateCompanyRoundRaisedValuationRoleEvidence

Nov 10, 2025ITIambic TherapeuticsScienceIambic Therapeutics (formerly Entos) is a clinical-stage life science and technology company developing…$8.4Mvaluation$476MraisedRecent roundsOversubscribed financing round (company described as >$100M) · Nov 2025$100M · Abingworth, Alexandria Venture Investments +15Series B extension (oversubscribed) · Jun 2024$50M · led by Exor Ventures, Mubadala CapitalSeries B (oversubscribed) · Oct 2023$100M · led by Abingworth, Ascenta CapitalIambic TherapeuticsOversubscribed financing round (company described as >$100M)$100M—Participant

Source ↗

Dec 12, 2024CCrusoeNeocloudsCrusoe is a vertically integrated AI infrastructure provider built around energy-first compute. The company says it…$10Bvaluation$3.8BraisedRecent roundsSeries E · Oct 2025$1.4B · led by Mubadala Capital, Valor Equity PartnersDebt financing (credit facility) · Jun 2025$750M · led by Brookfield Asset ManagementDebt financing (credit facility) · Mar 2025$225M · led by Upper90 Capital ManagementCrusoeSeries D$600M$2.8BParticipant

Source ↗+1 ↗

Sep 09, 2020RRecursionScienceRecursion is a clinical-stage TechBio company building an industrialized, AI-native drug discovery and development…$938.3MraisedRecent roundsPublic offering (underwritten) · Jun 2024$200M · Public shareholders (offering investors)Strategic investment (private investment in public equity / PIPE) · Jul 2023$50M · led by NVIDIAInitial Public Offering (IPO) / Public offering (pricing) · Apr 2021$436.4M · Baillie Gifford & Co. (clients incl. Scottish Mortgage Investment Trust plc), Mubadala Investment Company (entities affiliated) +1RecursionSeries D$239M—Participant

Source ↗+1 ↗

UndatedOOwkinSeries B (total disclosed by Owkin)$230M—Participant

Source ↗

DateCompanyRoundRaisedValuationRoleEvidence

Source ↗+1 ↗

UndatedOOwkinSeries B (total disclosed by Owkin)$230M—Participant

Source ↗